[go: up one dir, main page]

GB2611206A - Pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound - Google Patents

Pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound Download PDF

Info

Publication number
GB2611206A
GB2611206A GB2218187.9A GB202218187A GB2611206A GB 2611206 A GB2611206 A GB 2611206A GB 202218187 A GB202218187 A GB 202218187A GB 2611206 A GB2611206 A GB 2611206A
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
composition according
terpinene
compound
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB2218187.9A
Other versions
GB2611206B (en
GB202218187D0 (en
Inventor
Babikyan Yusef
Babikian Haig
Jiaravanon Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhea Genetics Pte Ltd
Original Assignee
Rhea Genetics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhea Genetics Pte Ltd filed Critical Rhea Genetics Pte Ltd
Publication of GB202218187D0 publication Critical patent/GB202218187D0/en
Publication of GB2611206A publication Critical patent/GB2611206A/en
Application granted granted Critical
Publication of GB2611206B publication Critical patent/GB2611206B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

There is disclosed a pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound.

Claims (28)

Claims
1. A pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound.
2. A pharmaceutical composition according to claim 1 , wherein the bisabolol compound is in an amount from about 10% to about 40% by weight of the total amount of the bisabolol compound, valencene and the terpinene compound.
3. A pharmaceutical composition according to claim 1 or 2, wherein the valencene is in an amount from about 22% to about 53% by weight of the total amount of the bisabolol compound, valencene and the terpinene compound.
4. A pharmaceutical composition according to any preceding claim, wherein the terpinene compound is in an amount from about 22% to about 53% by weight of the total amount of the bisabolol compound, valencene and the terpinene compound.
5. A pharmaceutical composition according to any preceding claim, wherein the bisabolol compound is alpha-bisabolol and/or beta-Bisabolol.
6. A pharmaceutical composition according to claim 5, wherein the bisabolol compound is alpha-bisabolol.
7. A pharmaceutical composition according to any preceding claim, wherein the terpinene compound is one or more of alpha-terpinene, beta-terpinene, gamma-terpenine or delta- terpenine,
8. A pharmaceutical composition according to claim 7, wherein the terpinene compound is gamma-terpinene.
9. A pharmaceutical composition according to any preceding claim, comprising alpha- bisabolene in an amount from about 10% to about 40% by weight, valencene in an amount from about 22% to about 54% by weight, and a terpinene compound in an amount from about 22% to about 54% by weight, wherein the terpinene compound is alpha terpinene, beta-terpinene or gamma terpinene.
10. A pharmaceutical composition according to any preceding claim, further comprising a carrier.
11. A pharmaceutical composition according to any preceding claim, wherein the carrier is a carrier oil.
12. A pharmaceutical composition according to any preceding claim, wherein the carrier oil comprises one or more of gardenia oil, cherry oil or pine oil .
13. A pharmaceutical composition according to claim 12 wherein the carrier oil further comprises olive oil.
14. A pharmaceutical composition according to any preceding claim, further comprising vitamin E.
15. A pharmaceutical composition according to any one of claims 1 to 4, wherein the composition comprises alpha-bisabolol, valencene, alpha-terpinene, olive oil, gardenia oil, cherry oil, pine oil and vitamin E.
16. A pharmaceutical composition according to any one of claims 1 to 4, wherein the composition comprises alpha-bisabolene, valencene, beta-terpinene, olive oil, gardenia oil, cherry oil, pine oil and vitamin E .
17. A pharmaceutical composition according to any one of claims 1 to 4, wherein the composition comprises alpha-bisabolene, valencene, gamma-terpinene, olive oil, gardenia oil, cherry oil, pine oil and vitamin E.
18. A pharmaceutical composition according to any one of claims 1 to 4 wherein the composition comprises alpha-bisabolene, valencene, gamma-terpinene and olive oil .
19. A pharmaceutical composition according to any preceding claim for use as a medicament.
20. A pharmaceutical composition according to any preceding claim for use in treating viral infections.
21. A pharmaceutical composition for use according to claim 20, wherein the viral infection is caused by a coronavirus or infectious bronchitis virus.
22. A pharmaceutical composition for use according to claim 21, wherein the coronavirus is SARS-CoV-2.
23. A pharmaceutical composition according to any one of claims 1 to 18 for use in the treatment of bacterial infections.
24. A pharmaceutical composition for use according to claim 23, wherein the bacteria responsible for the bacterial infection is selected from one or more of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Salmonella enteric serovar Typhimurium, Pseudomonas aeruginosa, or Micrococcus luteus.
25. A pharmaceutical composition according to any one of claims 1 to 18 for use in treating a fungal infection, for example a fungal infection caused by Candida albicans.
26. A pharmaceutical composition according to any one of claims 1 to 18 for use in preventing or treating cancer.
27. A method of treatment of a viral infection, a bacterial infection, a fungal infection and/or a method of preventing or treating cancer, comprising a step of administering to a subject a composition according to any one of claims 1 to 18 .
28. Use of a pharmaceutical composition according to any one of claims 1 to 18 in the manufacture of a medicament for treating a viral infection, a bacterial infection, a fungal infection and/or for preventing or treating cancer.
GB2218187.9A 2020-06-02 2021-06-02 A composition Active GB2611206B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2008289.7A GB202008289D0 (en) 2020-06-02 2020-06-02 A composition
PCT/IB2021/054832 WO2021245569A2 (en) 2020-06-02 2021-06-02 A composition

Publications (3)

Publication Number Publication Date
GB202218187D0 GB202218187D0 (en) 2023-01-18
GB2611206A true GB2611206A (en) 2023-03-29
GB2611206B GB2611206B (en) 2025-02-05

Family

ID=71526250

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2008289.7A Ceased GB202008289D0 (en) 2020-06-02 2020-06-02 A composition
GB2218187.9A Active GB2611206B (en) 2020-06-02 2021-06-02 A composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB2008289.7A Ceased GB202008289D0 (en) 2020-06-02 2020-06-02 A composition

Country Status (2)

Country Link
GB (2) GB202008289D0 (en)
WO (1) WO2021245569A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
US20190240191A1 (en) * 2013-09-18 2019-08-08 The Werc Shop, LLC Terpene-Based Compositions, Processes Methodologies
WO2021011413A1 (en) * 2019-07-12 2021-01-21 Atlas Hemp Company Llc. Methods for isolating essential oils, phytochemicals and pharmaceutically active components from biomass and reconstituting synthetic formulations comprising same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190240191A1 (en) * 2013-09-18 2019-08-08 The Werc Shop, LLC Terpene-Based Compositions, Processes Methodologies
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
WO2021011413A1 (en) * 2019-07-12 2021-01-21 Atlas Hemp Company Llc. Methods for isolating essential oils, phytochemicals and pharmaceutically active components from biomass and reconstituting synthetic formulations comprising same

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMBROZ MARTIN ET AL, "The Effects of Selected Sesquiterpenes from Myrica rubra Essential Oil on the Efficacy of Doxorubicin in Sensitive and Resistant Cancer Cell Lines", MOLECULES, vol. 22, no. 6, 20 June 2017 (2017-06-20), page 1021, DOI 10.3390/molecules22061021 See abstact and Conculsions; table *
ANTHONY J. DE LUCCA ET AL, "Fungicidal and Bactericidal Properties of Bisabolol and Dragosantol", THE JOURNAL OF ESSENTIAL OIL RESEARCH : JEOR, vol. 23, no. 3, 1 May 2011 (2011-05-01), pages 47-54, UK, DOI: 10.1080/10412905.2011.9700457 abstract *
BOUSBIA N ET AL, "A new process for extraction of essential oil from Citrus peels: Microwave hydrodiffusion and gravity", JOURNAL OF FOOD ENGINEERING, BARKING ESSEX, GB, vol. 90, no. 3, 1 February 2009 (2009-02-01), pages 409-413, ISSN: 0260-8774, DOI: 10.1016/J.JFOODENG.2008.06.034 [retrieved on 20 *
DA SILVA JOYCE KELLY R. ET AL, "Essential Oils as Antiviral Agents, Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation", INT. J. MOL. SCI., vol. 21, no 10, 12 May 2020 (2020-05-12) pages 3426, ISSN: 1661-6596, DOI: 10.3390/ijms21103426 Tabl 1, pg 8, Matricaria recu *
GUIMARÃES ALINE CRISTINA ET AL, "Antibacterial Activity of Terpenes and Terpenoids Present in Essential Oils", MOLECULES, (20190705), vol. 24, no. 13, 5 July 2019 (2019-07-05), page 2471, DOI:10.3390/molecules24132471 table 1 *
MAATALLAH S.; NASRI N.; HAJLAOUI H.; ALBOUCHI A.; ELAISSI A.: "Evaluation changing of essential oil of laurel (Laurus nobilisL.) under water deficit stress conditions", INDUSTRIAL CROPS AND PRODUCTS, ELSEVIER, NL, vol. 91, 19 July 2016 (2016-07-19), NL , pages 170 - 178, XP029681348, ISSN: 0926-6690, DOI: 10.1016/j.indcrop.2016.07.001 *
PERDONES ÁNGELA ET AL, "Effect of chitosan-lemon essential oil coatings on volatile profile of strawberries during storage", FOOD CHEMISTRY, ELSEVIER LTD, NL, vol. 197, 12 November 2015 (2015-11-12), pages 979-986, ISSN: 0308-8146, DOI: 10.1016/J.FOODCHEM.2015.11.054 table 2 *

Also Published As

Publication number Publication date
WO2021245569A3 (en) 2022-02-10
GB2611206B (en) 2025-02-05
WO2021245569A2 (en) 2021-12-09
GB202008289D0 (en) 2020-07-15
GB202218187D0 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
Pérez-Laguna et al. Antimicrobial photodynamic activity of Rose Bengal, alone or in combination with Gentamicin, against planktonic and biofilm Staphylococcus aureus
CA3257053A1 (en) Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
CR20200148A (en) Chromane monobactam compounds for the treatment of bacterial infections
ZA202300259B (en) Compound for the treatment of coronaviral infections
Gunjan et al. A comparative study of the effect of different topical agents on burn wound infections
WO2009043987A9 (en) Antibiotic compositions containing essential oils, prophylaxis and treatment of nosocomial diseases
Hendiani et al. Synthesis of silver nanoparticles and its synergistic effects in combination with imipenem and two biocides against biofilm producing Acinetobacter baumannii
Baiomy et al. Sensitizing multi drug resistant Staphylococcus aureus isolated from surgical site infections to antimicrobials by efflux pump inhibitors
WO2014165107A3 (en) Mannose derivatives for treating bacterial infections
FI3273968T3 (en) Minocycline compounds for biodefense
EP4606375A3 (en) Antibacterial compounds
BR112019018615A2 (en) antimicrobial compounds, compositions and uses thereof
EA202290048A1 (en) MEDICINE AND ITS USE FOR THE TREATMENT OF BACTERIAL INFECTIONS ASSOCIATED WITH BIOFILM
Bakar et al. Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphyloccus aureus
AR064152A1 (en) ANTIBACTERIAL QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PREPARATION METHOD.
Johann et al. Inhibitory effect of extracts from Brazilian medicinal plants on the adhesion of Candida albicans to buccal epithelial cells
GB2611206A (en) Pharmaceutical composition comprising: a bisabolol compound, valencene and a terpinene compound
Baishya et al. Establishment of a simple reproducible model for antibiotic sensitivity pattern study of biofilm forming Staphylococcus aureus
WO2015100448A3 (en) Multimodal antimicrobial therapy
WO2021209493A3 (en) Means and methods of preventing and treating infections
Adwan et al. In vitro interaction of certain antimicrobial agents in combination with plant extracts against multidrug-resistant Pseudomonas aeruginosa strains
Shamsuddin et al. Anti-methicillin resistant Staphylococcus aureus (MRSA) activity of an acetone extract from the leaves of Canarium odontophyllum (Miq.)
CL2023002840A1 (en) Rifamycin analogs in combination with vancomycin and uses thereof
MX2022012940A (en) Means and methods of preventing and treating infections.
WO2022115510A8 (en) Antimicrobial peptides and method of preventing or treating infection by using the same